Drill hole position in endoscopic anterior cruciate ligament reconstruction Results of an advanced arthroscopy course

D. Kohn,T. Busche,J. Carls

DOI: https://doi.org/10.1007/s001670050216

Abstract:

What problem does this paper attempt to address?

[Analysis of the nucleosome arrangement on satellite DNA].

Iu D Nechipurenko,M. V. Vol’kenshtein

Abstract:
Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

Xiaoyun Lu,Lei Yu,Zhang Zhang,Xiaomei Ren,Jeff B Smaill,Ke Ding

DOI: https://doi.org/10.1002/med.21488

Abstract:Both the first-generation reversible epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib and the second-generation covalent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib have significantly improved the survival of non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. However, a secondary EGFRT790M mutation leads to the clinically acquired resistance to the first- and second-generation EGFR-TKIs drugs. A number of the third-generation wild-type sparing EGFR inhibitors, for example, WZ4002, CO1686, AZD9291, HM61713, EGF816, ASP8173, and PF0674775, have been developed, among which AZD9291 has been approved by US FDA for the treatment of NSCLC patients with EGFRT790M . More recently, a tertiary EGFRC797S mutation was reported as the dominant resistance mechanism to the third-generation irreversible inhibitors. It is highly desirable to develop the fourth-generation EGFR inhibitors. This review summarizes the mechanisms of acquired resistance and the latest medicinal chemistry advances on the third- and fourth-generation EGFR inhibitors, with special attention being paid to the allosteric and reversible inhibitors combating the tertiary EGFRC797S mutation.
EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Yuxin Lin,Xian Wang,Hongchuan Jin

2014-01-01

Abstract:The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that plays a critical role in the initiation and development of malignant tumors via modulating downstream signaling pathways. In non-small cell lung cancer (NSCLC), the activating mutations located in the tyrosine kinase domains of EGFR have been demonstrated in multiple researches as the "Achilles' heel" of this deadly disease since they could be well-targeted by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clinical benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients. In order to make the most of EGFR-TKIs and develop more effective regimens for the NSCLC patients, researchers majoring in different aspects start a battle against EGFR-TKI resistance. Challenging as it is, we still progress stably and step firmly toward the final victory. This review will summarize the major mechanisms of acquired resistance to EGFR-TKIs, and then discuss the development of rationally designed molecular target drugs in accordance with each mechanism, in the hope of shedding light on the great achievements we have obtained and tough obstacles we have to overcome in the battle against this deadly disease.
Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.

S. Aher,A. Ohlsson

DOI: https://doi.org/10.1002/14651858.CD004865.pub3

IF: 8.4

2007-03-01

Cochrane Database of Systematic Reviews

Abstract:BACKGROUND Low plasma levels of erythropoietin (EPO) in preterm infants provide a rationale for the use of EPO to prevent or treat anaemia. OBJECTIVES To assess the effectiveness and safety of early versus late initiation of EPO in reducing red blood cell (RBC) transfusions in preterm and/or low birth weight (LBW) infants. SEARCH METHODS The standard search of the Cochrane Neonatal Review Group (CNRG) was performed in 2006 and updated in 2009. Updated search in September 2009 as follows: The Cochrane Library, MEDLINE (search via PubMed), CINAHL and EMBASE were searched from 2005 to September 2009. The searches were repeated in March 2012. The Pediatric Academic Societies' Annual meetings were searched electronically from 2000 to 2012 at Abstracts2View(TM) as were clinical trials registries (clinicaltrials.gov; controlled-trials.com; and who.int/ictrp). SELECTION CRITERIA Randomised or quasi-randomised controlled trials enrolling preterm or LBW infants less than eight days of age. INTERVENTION Early initiation of EPO (initiated at less than eight days of age) versus late initiation of EPO (initiated at eight to 28 days of age). DATA COLLECTION AND ANALYSIS The standard methods of the CNRG were followed. Weighted treatment effects included typical risk ratio (RR), typical risk difference (RD), number needed to treat to benefit (NNTB), number needed to treat to harm (NNTH) and mean difference (MD), all with 95% confidence intervals (CI). A fixed-effect model was used for meta-analyses and heterogeneity was evaluated using the I-squared (I(2)) test. MAIN RESULTS No new trials were identified in March of 2012. Two high quality randomised double-blind controlled studies enrolling 262 infants were identified. A non-significant reduction in the 'Use of one or more RBC transfusions' [two studies 262 infants; typical RR 0.91 (95% CI 0.78 to 1.06); typical RD -0.07 (95% CI -0.18 to 0.04; I(2) = 0% for both RR and RD] favouring early EPO was noted. Early EPO administration resulted in a non-significant reduction in the "number of transfusions per infant" compared with late EPO [typical MD - 0.32 (95% CI -0.92 to 0.29)]. There was no significant reduction in total volume of blood transfused per infant or in the number of donors to whom the infant was exposed. Early EPO led to a significant increase in the risk of retinopathy of prematurity (ROP) (all stages) [two studies, 191 infants; typical RR 1.40 (95% CI 1.05 to 1.86); typical RD 0.16 (95% CI 0.03 to 0.29); NNTH 6 (95% CI 3 to 33)]. There was high heterogeneity for this outcome (I(2) = 86% for RR and 81% for RD). Both studies (191 infants) reported on ROP stage ≥ 3. No statistically significant increase in risk was noted [typical RR 1.56 (95% CI 0.71 to 3.41); typical RD 0.05 (-0.04 to 0.14)] There was no heterogeneity for this outcome (0% for both RR and RD). No other important favourable or adverse neonatal outcomes or side effects were reported. AUTHORS' CONCLUSIONS The use of early EPO did not significantly reduce the 'Use of one or more RBC transfusions' or the 'Number of transfusions per infant" compared with late EPO administration. The finding of a statistically significant increased risk of ROP (any grade) and a similar trend for ROP stage ≥ 3 with early EPO treatment is of great concern.
CO-INFECTION OF TRANSGENIC PLUMS WITH PRUNUS NECROTIC AND PLUM POX VIRUSES

M. Ravelonandro,J. hily,P. Briard,M. Monsion,R. Scorza

DOI: https://doi.org/10.17660/ACTAHORTIC.2007.734.14

2007-02-01

Abstract:The reaction of the transgenic plum pox virus (PPV) resistant C-5 plum was studied under conditions of co-infection with Prunus necrotic ringspot virus (PNRSV) and PPV as may be encountered in the field. C-5 and controls were inoculated with PPV and PNRSV following several co-infection schemes. The results of this preliminary study showed that, as expected, the transgenic clones, including C-5 were not resistant to PNRSV. Furthermore, no PPV resistance breaking effects of the two viruses co-existing in C-5 were observed. In the susceptible clones, the data suggest that PNRSV infection might mask some symptoms of sharka disease (PPV). These synergistic effects are under investigation.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects

Henry Dickerson,Ahmad Diab,Othman Al Musaimi

DOI: https://doi.org/10.3390/ijms251810008

2024-09-17

Abstract:Tyrosine kinase inhibitors (TKIs) have emerged as a leading targeted cancer therapy, reducing the side effects often seen with non-targeted treatments, especially the damage to healthy cells. To tackle resistance, typically caused by epidermal growth factor receptor (EGFR) mutations, four generations of TKIs have been developed. Each generation has shown improved effectiveness and fewer side effects, resulting in better patient outcomes. For example, patients on gefitinib, a first-generation TKI, experienced a progression-free survival (PFS) of 10 months compared to 5 months with conventional chemotherapy. Second-generation TKI afatinib outperformed erlotinib and extended PFS to 11.1 months compared to 6.9 months with cisplatin. Third-generation TKIs further increased survival to 38.6 months, compared to 31.8 months with first-generation TKIs. This progress demonstrates the ability of newer TKIs to overcome resistance, particularly the T790M mutation, while reducing adverse effects. Ongoing research focuses on overcoming resistance from newer mutations like C797S to further improve patient survival. These developments highlight the significant progress in TKI therapy and the continued effort to refine cancer treatment. Recent research in South Korea shows that third-generation TKIs are ineffective against non-small cell lung cancer (NSCLC) with the C797S mutation. Several trials have started showing promising in vitro and in vivo results, but more trials are needed before clinical approval. This review underscores notable advancements in the field of EGFR TKIs, offering a comprehensive analysis of their mechanisms of action and the progression of various TKI generations in response to resistance.
Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations

Hao Chen,Mengzhen Lai,Tao Zhang,Yuqing Chen,Linjiang Tong,Sujie Zhu,Yang Zhou,Xiaomei Ren,Jian Ding,Hua Xie,Xiaoyun Lu,Ke Ding

DOI: https://doi.org/10.1021/acs.jmedchem.2c00168

IF: 8.039

2022-04-21

Journal of Medicinal Chemistry

Abstract:Tertiary C797S mutation of epidermal growth factor receptor (EGFR)-mediated resistance in non-small-cell-lung-cancer (NSCLC) patients is still an unmet clinical need. Several classes of adenosine 5'-triphosphate-competitive or allosteric EGFRT790M/C797S inhibitors and degraders have been developed, but none of them have received approval from the regulatory agencies. Herein, we report the structure-based design of conformational constrained 4-(1-ethylsufonyl-3-indolyl)-2-phenylaminopyrimidines as new EGFRT790M/C797S inhibitors by using a macrocyclization strategy. Representative compound 18j potently inhibited EGFR19del/T790M/C797S and EGFRL858R/T790M/C797S mutants with IC50 values of 15.8 and 23.6 nM and suppressed Ba/F3-EGFRL858R/T790M/C797S and Ba/F3-EGFR19del/T790M/C797S cells with IC50 values of 0.036 and 0.052 μM, respectively, which is 10-20-fold more potent than brigatinib. 18j also potently inhibited the EGFR19del/T790M/C797S-mutated PC-9-OR NSCLC cell proliferation with an IC50 value of 0.644 μM but was less potent for parental Ba/F3 and A431 cells. This study provides a new lead compound for drug discovery to combat EGFRC797S-mediated resistance in NSCLC patients.

chemistry, medicinal
Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Hengmiao Cheng,Sajiv K Nair,Brion W Murray,Chau Almaden,Simon Bailey,sangita m baxi,douglas carl behenna,Sujin Cho-Schultz,deepak k dalvie,Dac M Dinh,Martin P Edwards,Jun Li Feng,Rose Ann Ferre,Ketan S Gajiwala,Michelle D Hemkens,Amy Jackson-Fisher,Mehran Jalaie,theodore o johnson,robert steven kania,Susan Kephart,Jennifer Lafontaine,elizabeth a lunney,Kevin K-C Liu,Zhengyu Liu,jean j matthews,Asako Nagata,Sherry Niessen,Martha A Ornelas,suvi tuula marjukka orr,Mason Pairish,simon paul planken,Shijian Ren,daniel tyler richter,kevin m ryan,neal w sach,Hong Shen,Tod Smeal,james solowiej,scott channing sutton,Khanh Tran,Elaine Tseng,william f vernier,Marlena Walls,Shuiwang Wang,Scott L Weinrich,Shuibo Xin,Haiwei Xu,Min-Jean Yin,Michael Zientek,m zientek,john charles kath

DOI: https://doi.org/10.1021/acs.jmedchem.5b01633

IF: 8.039

2016-01-01

Journal of Medicinal Chemistry

Abstract:First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M). Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR. As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort. PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (0 high potency and specificity to the T790M-containing double mutant EGFRs, (ii) minimal intrinsic chemical reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR
[Custom-made mouthguards and prevention of orofacial injuries in sports].

T. Badel,V. Jerolimov,J. Pandurić,V. Carek

Abstract:The importance of sports dentistry has become even greater due to the role that sports have in modern society. As the risk of sports-related injuries appears already in the period of children's play and is constantly present in various risk-related sporting activities, the role of dental profession has become extremely important. Custom-made mouthguards are the most highly recommended mouthguards used for successful prevention of orofacial and dental injuries. It is important to inform athletes of the best characteristics of a custom-made mouthguard such as retention, comfort, fit, ease of speech, resistance to tearing, ease of breathing as well as good protection of the teeth, gingiva and lips. The shape and surface of the mouthguard which encloses the teeth, the gingival and the hard palate can vary depending on the anatomical features of the athlete's jaw, his/her dental arch, the type of sports activity, as well as the materials used in the manufacture of the mouthguard. Mouthguards should not extend distally further than the first molars because some athletes complain of the vomiting reflex. In addition, mouthguards may interfere with breathing. They should reach the mucogingival border labially and extend a few millimeters palatally in order to provide the best protection for the labial gingival and good retention. The labial flange should extend up to 2 mm of the vestibular reflection. The palatal flange should extend about 10 mm above the gingival margin thus enclosing the greatest part of the anterior palate surface with a slight narrowing distally not further than the first molars. Materials used in the manufacture of mouthguards should satisfy a number of physical, mechanical and biological requirements. Essential properties of materials used in the manufacture of mouthguards include water absorption, density, thickness as well as temperature transmission, energy absorption and drawing strength (tensile strength) of custom-made mouthguards. Such materials should have an optimal consistency in order to cushion the traumatic impact. Currently, ethylene-vinyl acetate (EVA) is the most commonly used mouthguard material. An optimal thickness of the mouthguard is achieved by the application of vacuum forming pressure-lamination technique in two layers of a thermoplastic sheet of EVA copolymer and if needed, by placing two layers of protective air-cells against the critical area. Some investigations in the Croatian samples showed that the most common injuries in water polo occur in the orofacial region (96.4% of cases), of which 80% are injuries of lips, tongue and cheek. In the period from 1997 to 2005 the number of orofacial injuries increased by 62%. Dental trauma occurs in 7.6% of cases. In basketball players soft tissue injury in the orofacial complex was established in 69.4% and dental trauma in 11.3% of the respondents. In the selected sample of handball players, soft tissue injuries were established in 78.8%, dental trauma and loss of teeth in 13.6% and temporomandibular joint injuries in 6.8% of the cases. In tae-kwon-do players 88% of orofacial injuries were lacerations, but only 12% reported dental and temporomandibular joint trauma. Only a half of the examined professional basketball players wore mouthguards, and none of the examined tae-kwon-do players. Clinical value of intraoral custom-made mouthguards was proven. Dentists play the key role in the prevention and treatment of sports-related dental and orofacial injuries, collection and dissemination of relevant information, as well as promotion of research on the preventive procedures related to injuries of such a specific aetiology.
Acquired Resistance to Third-Generation EGFR-TKIs and Emerging Next-Generation EGFR Inhibitors

Xiaojing Du,Biwei Yang,Quanlin An,Yehuda G. Assaraf,Xin Cao,Jinglin Xia

DOI: https://doi.org/10.1016/j.xinn.2021.100103

2021-01-01

Innovation

Abstract:The discovery that mutations in the EGFR gene are detected in up to 50% of lung adenocarcinoma patients, along with the development of highly efficacious epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), has revolutionized the treatment of this frequently occurring lung malignancy. Indeed, the clinical success of these TKIs constitutes a critical milestone in targeted cancer therapy. Three generations of EGFR-TKIs are currently approved for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). The first-generation TKIs include erlotinib, gefitinib, lapatinib, and icotinib; the second-generation ErbB family blockers include afatinib, neratinib, and dacomitinib; whereas osimertinib, approved by the FDA on 2015, is a third-generation TKI targeting EGFR harboring specific mutations. Compared with the first- and second-generation TKIs, third-generation EGFR inhibitors display a significant advantage in terms of patient survival. For example, the median overall survival in NSCLC patients receiving osimertinib reached 38.6 months. Unfortunately, however, like other targeted therapies, new EGFR mutations, as well as additional drug-resistance mechanisms emerge rapidly after treatment, posing formidable obstacles to cancer therapeutics aimed at surmounting this chemoresistance. In this review, we summarize the molecular mechanisms underlying resistance to third-generation EGFR inhibitors and the ongoing efforts to address and overcome this chemoresistance. We also discuss the current status of fourth-generation EGFR inhibitors, which are of great value in overcoming resistance to EGFR inhibitors that appear to have greater therapeutic benefits in the clinic.
Advances in research on EGFR-TKI resistance mechanism and therapeutic strategies in non-small cell lung cancer

Jun Jiang

DOI: https://doi.org/10.3760/CMA.J.ISSN.1673-436X.2020.01.013

2020-01-05

Abstract:Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are of great significance for the treatment of patients with non-small cell lung cancer.First-generation EGFR-TKI (such as gefitinib and erlotinib) or second-generation EGFR-TKI (such as afatinib and dacomitinib) are effective in the treatment of EGFR-mutant non-small cell lung cancer, especially EGFR exon 19 deletion or exon 21 L858R mutation.However, due to acquired resistance, almost all cases will relapse after 1 to 2 years.The most common resistance mutation is the EGFR T790M secondary mutation in exon 20.Osimertinib is a third-generation EGFR-TKI targeting T790M mutation and has been shown to be highly potent against EGFR-mutant lung cancer.However, the occurrence of acquired resistance to the C797S tertiary mutation of the third generation EGFR-TKI has been observed.This article reviews these resistance mechanisms and discuss strategies for coping with EGFR-TKI resistance. Key words: Carcinoma, non-small-cell lung; Receptor, epidermal growth factor; Drug resistance, neoplasm; Epidermal growth factor receptor tyrosine kinase inhibitor

Medicine
Guest editorial: another new frontier: hip arthroscopy.

J. Tasto

2008-12-01

Abstract:
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Dalia Ercan,Hwan Geun Choi,Cai-Hong Yun,Marzia Capelletti,Ting Xie,Michael J. Eck,Nathanael S. Gray,Pasi A. Jaenne

DOI: https://doi.org/10.1158/1078-0432.ccr-14-2789

IF: 13.801

2015-01-01

Clinical Cancer Research

Abstract:Purpose: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, includingWZ4002, CO-1686, and AZD9291, are effective in preclinical models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation. However, little is known about how cancers develop acquired resistance to this class of EGFR inhibitors. We sought to identify and study EGFR mutations that confer resistance to this class of agents.Experimental Design: We performed an N-ethyl-N-nitrosourea (ENU) mutagenesis screen in EGFR-mutant (sensitizing alone or with concurrent EGFR T790M) Ba/F3 cells and selected drug-resistant clones. We evaluated the sensitivity of EGFR inhibitors in models harboring drug-resistant EGFR mutations.Results: We identified 3 major drug resistance mutations. EGFR L718Q, L844V, and C797S cause resistance to both WZ4002 and CO-1686 while, in contrast, only EGFR C797S leads to AZD9291 resistance. Cells containing an EGFR-sensitizing mutation, Del 19 or L858R, in conjunction with L718Q, L844V, or C797S retain sensitivity to quinazoline-based EGFR inhibitors, gefitinib and afatinib. The C797S mutation, in the presence of Del 19 or L858R and T790M, causes resistance to all current EGFR inhibitors, but L858R/T790M/C797S remains partially sensitive to cetuximab which leads to disruption of EGFR dimerization.Conclusions: Our findings provide insights into resistance mechanisms to irreversible pyrimidine-based EGFR inhibitors and identify specific genomic contexts in which sensitivity is retained to existing clinical EGFR inhibitors. These findings will guide the development of new strategies to inhibit EGFR. (C)2015 AACR.
Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer

Xiaoxue Wang,Zhongxiang Qin,Wenrui Qiu,Kejia Xu,Yuting Bai,Beilei Zeng,Yakun Ma,Shuang Yang,Yi Shi,Yan Fan

DOI: https://doi.org/10.1016/j.ejmech.2024.116711

2024-11-05

Abstract:To overcome C797S mutation, the latest and most common resistance mechanism in the clinical treatment of third-generation EGFR inhibitor, a novel series of substituted 6-(2-aminopyrimidine)-indole derivatives were designed and synthesized. Through the structure-activity relationship (SAR) study, compound 11eg was identified as a novel and potent EGFR L858R/T790M/C797S inhibitor (IC50 = 0.053 μM) but had a weak effect on EGFRWT (IC50 = 1.05 μM). 11eg significantly inhibited the proliferation of the non-small cell lung cancer (NSCLC) cells harboring EGFRL858R/T790M/C797S with an IC50 of 0.052 μM. 11eg also showed potent inhibitory activity against other NSCLC cell lines harboring main EGFR mutants. Furthermore, 11eg exhibited much superior activity in arresting cell cycle and inducing apoptosis of NSCLC cells with mutant EGFRC797S. It blocked cellular EGFR signaling. Importantly, 11eg markedly suppressed the tumor growth in in vivo xenograft mouse model with good safety. Additionally, 11eg displayed good microsomal stability. These results demonstrated the potential of 11eg with novel scaffold as a promising lead compound targeting EGFRC797S to guide in-depth structural optimization.
Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective

Jing Zhu,Qian Yang,Weiguo Xu

DOI: https://doi.org/10.3390/pharmaceutics13091500

IF: 6.525

2021-09-18

Pharmaceutics

Abstract:Molecular targeted therapy has been reported to have fewer adverse effects, and offer a more convenient route of administration, compared with conventional chemotherapy. With the development of sequencing technology, and research on the molecular biology of lung cancer, especially whole-genome information on non-small cell lung cancer (NSCLC), various therapeutic targets have been unveiled. Among the NSCLC-driving gene mutations, epidermal growth factor receptor (EGFR) mutations are the most common, and approximately 10% of Caucasian, and more than 50% of Asian, NSCLC patients have been found to have sensitive EGFR mutations. A variety of targeted therapeutic agents for EGFR mutations have been approved for clinical applications, or are undergoing clinical trials around the world. This review focuses on: the indications of approved small molecular kinase inhibitors for EGFR mutation-positive NSCLC; the mechanisms of drug resistance and the corresponding therapeutic strategies; the principles of reasonable and precision molecular structure; and the drug development discoveries of next-generation inhibitors for EGFR.

pharmacology & pharmacy
Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation

Ying Wang,Qian Liu,Chunhong Chu,Lanxin Li,Zhenxing Wang,Qiyu Liu,Guangyao Wu,Xiangkai Wei,Lei An,Jiguang Ma

DOI: https://doi.org/10.1016/j.taap.2023.116385

IF: 4.46

2023-02-01

Toxicology and Applied Pharmacology

Abstract:Lung cancer, the leading cause of cancer-related mortality, is the most commonly diagnosed cancer. Tyrosine kinase inhibitors (TKIs) are considered a drug-targeted therapy for non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, limited data are available involving the activity of EGFR TKIs against rare EGFR mutations. Here, based on an endogenous EGFR-depleted cell Line H3255 by CRISPR, H3255 cells with rare mutant EGFRS768I and compound mutations EGFRS768I+L858R were tested using cell proliferation assay, cytotoxicity, membrane potential, flow cytometry and Western blot analysis. We conducted cytotoxicity screening of EGFR mutations on six front-line TKIs based on first-, second-, and third-generation TKIs (afatinib, dacomitinib, osimertinib, erlotinib, gefitinib, and icotinib). The results showed that the sensitivity of these mutants containing rare variants EGFRS768I to six front-line TKIs was enriched in the irreversible TKI cytotoxicity assays by determining their change in cytotoxicity, apoptosis, cell proliferation and signal pathway factors. Importantly, the variants harboring EGFRL858R (H3255), EGFRS768I (H3255S768I) and EGFRS768I+L858R (H3255S768I+L858R) were sensitive to six TKIs and induced cytotoxicity through different pathways. Moreover, the compound mutations EGFRS768I+L858R showed more TKI resistance than EGFRS768I mutation and EGFRL858R mutation. We present a comprehensive reference for the sensitivity of EGFRS768I variants to six front-line TKIs. For patients with the EGFR S768I mutation and compound mutations EGFRS768I+L858R, six first-line TKIs appear to be reasonable therapeutic options.

pharmacology & pharmacy,toxicology
Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform

Hideyuki Igawa,Zef A Konst ,Eric Therrien,Mee Shelley,Pieter H Bos ,Ana Negri ,Andreas Verras,Jiaye Guo,Markus Dahlgren,Adam Levinson,Brendan T Parr,Suresh E Kurhade,Prashant Latthe,Rajesha Shetty ,Sridhar Santhanakrishnan ,Katie Amberg-Johnson ,Alan Futran,Chris Atsriku,Robert Pelletier,Zhijian Liu,Jeffery A Bell,Sathesh Bhat,Mats Svensson ,Aleksey I Gerasyuto,Heidi Koldsø

DOI: https://doi.org/10.26434/chemrxiv-2024-5rzt9

2024-06-19

Abstract:Despite the success of first, second and third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in treatment of non-small cell lung cancer (NSCLC) with classical EGFR mutations (L858R or Exon 19 deletions), disease progression often occurs due to the acquisition of additional mutations in the EGFR kinase domain that confer TKI resistance. Specifically, acquisition of both T790M and C797S resistance mutations results in an EGFR variant that is resistant to all approved EGFR TKIs. Herein, we report a physics-based computationally-driven lead identification approach which successfully identified structurally-unique imidazo[3.2-b]pyrazole derivatives as reversible inhibitors of EGFR classical mutations bearing both T790M and C797S. Importantly, they spare EGFR WT to avoid known EGFR WT-driven cutaneous toxicities. During profiling of imidazo[3.2-b]pyrazole derivatives, we elucidated the bioactivation mechanism causing CYP3A4/5 time-dependent inhibition (TDI) and found key modifications to suppress bioactivation and mitigate the TDI risk. Representative lead compound 31 inhibited EGFR L858R/T790M/C797S in biochemical assays with a Ki = 2.1 nM, and EGFR del19/T790M/C797S in a Ba/F3 cellular assay with a IC50 = 56.9 nM. Deuterated analog of 31 (38) demonstrated dose-dependent tumor growth inhibition in a Ba/F3 EGFR del19/T790M/C797S CDX model by 47% at 50 mg/kg BID and 92% at 100 mg/kg BID.

Chemistry
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence

Xiaochun Wang,David Goldstein,Philip J Crowe,Jia-Lin Yang

DOI: https://doi.org/10.2147/OTT.S94745

2016-09-06

Abstract:Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor (EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non-small-cell lung cancer (NSCLC). There have been three generations of the EGFR/HER-TKIs. First-generation EGFR/HER-TKIs, binding competitively and reversibly to the ATP-binding site of the EGFR TK domain, show a significant breakthrough treatment in selected NSCLC patients with activating EGFR mutations (actEGFRm) EGFR (L858R) and EGFR (Del19), in terms of safety, efficacy, and quality of life. However, all those responders inevitably develop acquired resistance within 12 months, because of the EGFR (T790M) mutation, which prevents TKI binding to ATP-pocket of EGFR by steric hindrance. The second-generation EGFR/HER-TKIs were developed to prolong and maintain more potent response as well as overcome the resistance to the first-generation EGFR/HER-TKIs. They are different from the first-generation EGFR/HER-TKIs by covalently binding to the ATP-binding site, irreversibly blocking enzymatic activation, and targeting EGFR/HER family members, including EGFR, HER2, and HER4. Preclinically, these compounds inhibit the enzymatic activation for actEGFRm, EGFR (T790M), and wtEGFR. The second-generation EGFR/HER-TKIs improve overall survival in cancer patients with actEGFRm in a modest way. However, they are not clinically active in overcoming EGFR (T790M) resistance, mainly because of dose-limiting toxicity due to simultaneous inhibition against wtEGFR. The third-generation EGFR/HER-TKIs selectively and irreversibly target EGFR (T790M) and actEGFRm while sparing wtEGFR. They yield promising efficacy in NSCLC patients with actEGFRm as well as EGFR (T790M) resistant to the first- and second-generation EGFR-TKIs. They also appear to have a lower incidence of toxicity due to the reduced inhibitory effect on wtEGFR. Currently, the first-generation EGFR/HER-TKIs gefitinib and erlotinib and second-generation EGFR/HER-TKI afatinib have been approved for use as the first-line treatment of metastatic NSCLC with actEGFRm. This review will summarize and evaluate a broad range of evidence of recent development of EGFR/HER-TKIs, with a focus on the second- and third-generation EGFR/HER-TKIs, in the treatment of patients with NSCLC harboring EGFR mutations.
Structure of the first transmembrane domain of the neuronal acetylcholine receptor beta2 subunit.

V. Bondarenko,Yan Xu,P. Tang

DOI: https://doi.org/10.1529/BIOPHYSJ.106.095364

IF: 3.4

2008-07-08

Biophysical Journal

Abstract:The recent cryoelectron microscopy structure of the Torpedo nicotinic acetylcholine receptor (nAChR) at 4-A resolution shows long helices for all transmembrane (TM) domains. This is in disagreement with several previous reports that the first TM domain of nAChR and other Cys-loop receptors are not entirely helical. In this study, we determined the structure and backbone dynamics of an extended segment encompassing the first TM domain (TM1e) of nAChR beta(2) subunit in dodecylphosphocholine micelles, using solution-state NMR and circular dichroism (CD) spectroscopy. Both CD and NMR results show less helicity in TM1e than in Torpedo nAChR structure (Protein Data Bank: 2BG9). The helical ending residues at the C-terminus are the same in the TM1e NMR structure and the Torpedo nAChR structure, but the helical starting residue (I-217) in TM1e is seven residues closer to the C-terminus. Interestingly, the helical starting residue is two residues before the highly conserved P-219, in accordance with the hypothesis that proline causes helical distortions at three residues preceding it. The NMR relaxation measurements show a dynamics pattern consistent with TM1e structure. The substantial nonhelical content adds greater flexibilities to TM1e, thereby implicating a different molecular basis for nAChR function compared to a longer and more rigid helical TM1.
EGFR kinase mutations in NSCLC: Unexpected structural and kinetic insights into the mechanism of the T790M resistance mutation and its inhibition by irreversible inhibitors including HKI-272

Cai-Hong Yun,Michelle Woo,Heidi Greulich,Matthew Meyerson,Kwok-Kin Wong,Michael J. Eck

IF: 11.2

2007-01-01

Cancer Research

Abstract:LB-367 Somatic mutations in the EGFR kinase are a cause of non-small cell lung cancer, and the presence of these mutations correlates with response to small-molecule tyrosine kinase inhibitors. Despite initial responses, longer-term efficacy of TKIs targeting the EGFR has been limited by the emergence of drug resistance, often conferred by an additional mutation of Threonine 790 in the EGFR to Methionine (T790M). This mutation, which lies in the ATP binding pocket of the kinase, confers resistance to anilinoquinazoline inhibitors including gefitinib and erlotinib. Importantly, the T790M mutant remains sensitive to a number of irreversible inhibitors, including HKI-272, Cl-387,785 and Cl-1033. These irreversible inhibitors are expected to bind in the ATP binding cleft in a manner analogous to similar reversible inhibitors, but they have an additional reactive group that forms a covalent bond with Cys 773 at the edge of the ATP binding cleft. The activity of these inhibitors against the T790M mutant therefore presents a paradox â\#8364;“ the steric effects of the T790M mutation that are presumed to underlie resistance to reversible anilinoquinazoline inhibitors should also interfere with the targeting of the irreversible inhibitors. To better understand the effects of the T790M mutant and the mechanism by which it confers resistance, we have determined the structure of this mutant alone and in complex with irreversible inhibitor HKI-272. Additionally, we have studied the kinetics and inhibitor-binding properties of the T790M mutant, the L858R/T790M double mutant, and the wild-type EGFR kinase. Surprisingly, using a direct binding assay we find that gefitinib binds to the T790M and L858R/T790M mutants with low nanomolar affinity (Kd=~5 nM), indicating that the T790M substitution does not sterically block gefitinib binding. These results are further supported by the crystal structure of HKI-272 in complex with the T790M mutant, which shows that the binding mode of HKI-272 is the same as that expected in the wild-type kinase. Kinetic analysis of the T790M mutant shows that it is approximately 5-fold more active that the wild-type kinase, with a similar Km for ATP. Interestingly, the L858R/T790M double mutant also has a Km for ATP equivalent to that of the wild-type kinase, whereas the L858R and G719S single mutants have markedly impaired affinity for ATP. Collectively, our findings indicate that much of the resistance induced by the T790M mutation may stem from its ability to restore wild-type affinity for ATP, rather than from its steric effects on inhibitor binding as was previously supposed. Since TKIs must compete with ATP to achieve their intended effect, their effective potency is diminished by the enhanced ATP-affinity. Irreversible inhibitors, as a class, overcome this effect through covalent binding.

Drill hole position in endoscopic anterior cruciate ligament reconstruction Results of an advanced arthroscopy course

[Analysis of the nucleosome arrangement on satellite DNA].

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.

CO-INFECTION OF TRANSGENIC PLUMS WITH PRUNUS NECROTIC AND PLUM POX VIRUSES

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

[Custom-made mouthguards and prevention of orofacial injuries in sports].

Acquired Resistance to Third-Generation EGFR-TKIs and Emerging Next-Generation EGFR Inhibitors

Advances in research on EGFR-TKI resistance mechanism and therapeutic strategies in non-small cell lung cancer

Guest editorial: another new frontier: hip arthroscopy.

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective

Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence

Structure of the first transmembrane domain of the neuronal acetylcholine receptor beta2 subunit.

EGFR kinase mutations in NSCLC: Unexpected structural and kinetic insights into the mechanism of the T790M resistance mutation and its inhibition by irreversible inhibitors including HKI-272